Scholars Central

Conference abstractPublished 15 Aug 2016

A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) Intensity Modulated Radiation Therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute

Authors: Anussara P. Songthong

King Chulalongkorn Memorial Hospital, Thailand

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: To investigate acute and late toxicities comparing sequential (SEQ-IMRT) versus Simultaneous Integrated Boost- Intensity Modulated Radiotherapy (SIB-IMRT) in Naso Pharyngeal Carcinoma (NPC) patients. Methods: Newly diagnosed stage I-IVB NPC patients were randomized to receive SEQ-IMRT or SIB-IMRT, with or without chemotherapy. SEQ-IMRT consisted of two sequential radiation treatment plans: 2Gy x 25 fractions to low-risk planning target volume (PTV-LR) followed by 2Gy x 10 fractions to high-risk planning target volume (PTV-HR). In contrast, SIB-IMRT consisted of only one treatment plan: 2.12Gy and 1.7Gy x 33 fractions to PTV-HR and PTV-LR, respectively. Toxicities were evaluated according to CTCAE version 4.0. Results: Between October 2010 and November 2013, 122 eligible patients were randomized between SEQ-IMRT (54 patients) and SIB-IMRT (68 patients). With median follow-up time of 16.8 months, there was no significant difference in toxicities between the two IMRT techniques. During chemoradiation, the most common grade 3-5 acute toxicities were mucositis (15.4% vs 13.6%, SEQ vs SIB, p=0.788) followed by dysphagia (9.6% vs 9.1%, p=1.000) and xerostomia (9.6% vs 7.6%, p=0.748). During the adjuvant chemotherapy period, 25.6% and 32.7% experienced grade 3 weight loss in SEQ-IMRT and SIB-IMRT (p=0.459). One-year overall survival (OS) and progression-free survival (PFS) were 95.8% and 95.5% in SEQ-IMRT and 98% and 90.2% in SIB-IMRT, respectively (p =0.472 for OS and 0.069 for PFS). Conclusion: This randomized, phase II/III trial comparing SIB-IMRT versus SEQ-IMRT in NPC showed no statistically significant difference between both IMRT techniques in terms of acute adverse events. Short-term tumor control and survival outcome were promising.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Anussara P. Songthong”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels